Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00151242 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00151242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00151242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
University of Ulm
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2004
Completion date
August 31, 2013
Enrollment
920 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia